Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer

Cheng Jeng Tai, Chin Kwun Pan, Ching Shyang Chen, Chin Sheng Hung, Chih Hsiung Wu, Hung Yi Chiou

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: The optimal duration of adjuvant trastuzumab treatment in patients with HER2-positive breast cancer is not known. The aim of this study was to evaluate the efficacy of 6 months of adjuvant trastuzumab treatment in patients with stage II or III HER2-positive breast cancer. Methods: The records of patients with HER2-positive stage II or III breast cancer who were admitted to the Breast Center of Taipei Medical University Hospital and Yuan's General Hospital between 2000 and 2008 were reviewed. All patients received adjuvant trastuzumab at an initial dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg/week for 22 weeks in combination with chemotherapy. Results: A total of 51 patients were included with a mean age of 46.9 years. Approximately 55% of the patients had stage III disease. The mean follow-up time from initiation of treatment was 45.2 months (range, 0.9 to 85 months). During follow-up, 46 patients (90.2%) did not experience tumor recurrence. The mean estimated disease free survival was 80.2 months. The estimated 1- , 2-, 5-, and 7-yearsurvival rates were 97.9%, 93.1%, 93.1%, and 93.1%, respectively. The most common adverse effects were gastrointestinal symptoms (21.6%), chills (17.6%), dizziness (9.8%), and bone pain (7.8%). No cardiac or hematologic adverse events occurred. Conclusion: Adjuvant therapy with trastuzumab for 6 months resulted in a clinical benefit in patients with HER2-positive breast cancer.

Original languageEnglish
Pages (from-to)1981-1984
Number of pages4
JournalAsian Pacific Journal of Cancer Prevention
Volume14
Issue number3
DOIs
Publication statusPublished - 2013

Fingerprint

Breast Neoplasms
Chills
Trastuzumab
Dizziness
Therapeutics
Combination Drug Therapy
General Hospitals
Disease-Free Survival
Breast
Bone and Bones
Recurrence
Pain
Neoplasms

Keywords

  • 2 positive
  • Breast cancer
  • Clinical benefit
  • Her
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Public Health, Environmental and Occupational Health
  • Epidemiology

Cite this

Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer. / Tai, Cheng Jeng; Pan, Chin Kwun; Chen, Ching Shyang; Hung, Chin Sheng; Wu, Chih Hsiung; Chiou, Hung Yi.

In: Asian Pacific Journal of Cancer Prevention, Vol. 14, No. 3, 2013, p. 1981-1984.

Research output: Contribution to journalArticle

@article{ad89d4dbeace47e1bd7e5e454a9b95fd,
title = "Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer",
abstract = "Objective: The optimal duration of adjuvant trastuzumab treatment in patients with HER2-positive breast cancer is not known. The aim of this study was to evaluate the efficacy of 6 months of adjuvant trastuzumab treatment in patients with stage II or III HER2-positive breast cancer. Methods: The records of patients with HER2-positive stage II or III breast cancer who were admitted to the Breast Center of Taipei Medical University Hospital and Yuan's General Hospital between 2000 and 2008 were reviewed. All patients received adjuvant trastuzumab at an initial dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg/week for 22 weeks in combination with chemotherapy. Results: A total of 51 patients were included with a mean age of 46.9 years. Approximately 55{\%} of the patients had stage III disease. The mean follow-up time from initiation of treatment was 45.2 months (range, 0.9 to 85 months). During follow-up, 46 patients (90.2{\%}) did not experience tumor recurrence. The mean estimated disease free survival was 80.2 months. The estimated 1- , 2-, 5-, and 7-yearsurvival rates were 97.9{\%}, 93.1{\%}, 93.1{\%}, and 93.1{\%}, respectively. The most common adverse effects were gastrointestinal symptoms (21.6{\%}), chills (17.6{\%}), dizziness (9.8{\%}), and bone pain (7.8{\%}). No cardiac or hematologic adverse events occurred. Conclusion: Adjuvant therapy with trastuzumab for 6 months resulted in a clinical benefit in patients with HER2-positive breast cancer.",
keywords = "2 positive, Breast cancer, Clinical benefit, Her, Trastuzumab",
author = "Tai, {Cheng Jeng} and Pan, {Chin Kwun} and Chen, {Ching Shyang} and Hung, {Chin Sheng} and Wu, {Chih Hsiung} and Chiou, {Hung Yi}",
year = "2013",
doi = "10.7314/APJCP.2013.14.3.1981",
language = "English",
volume = "14",
pages = "1981--1984",
journal = "Asian Pacific Journal of Cancer Prevention",
issn = "1513-7368",
publisher = "Asian Pacific Organization for Cancer Prevention",
number = "3",

}

TY - JOUR

T1 - Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer

AU - Tai, Cheng Jeng

AU - Pan, Chin Kwun

AU - Chen, Ching Shyang

AU - Hung, Chin Sheng

AU - Wu, Chih Hsiung

AU - Chiou, Hung Yi

PY - 2013

Y1 - 2013

N2 - Objective: The optimal duration of adjuvant trastuzumab treatment in patients with HER2-positive breast cancer is not known. The aim of this study was to evaluate the efficacy of 6 months of adjuvant trastuzumab treatment in patients with stage II or III HER2-positive breast cancer. Methods: The records of patients with HER2-positive stage II or III breast cancer who were admitted to the Breast Center of Taipei Medical University Hospital and Yuan's General Hospital between 2000 and 2008 were reviewed. All patients received adjuvant trastuzumab at an initial dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg/week for 22 weeks in combination with chemotherapy. Results: A total of 51 patients were included with a mean age of 46.9 years. Approximately 55% of the patients had stage III disease. The mean follow-up time from initiation of treatment was 45.2 months (range, 0.9 to 85 months). During follow-up, 46 patients (90.2%) did not experience tumor recurrence. The mean estimated disease free survival was 80.2 months. The estimated 1- , 2-, 5-, and 7-yearsurvival rates were 97.9%, 93.1%, 93.1%, and 93.1%, respectively. The most common adverse effects were gastrointestinal symptoms (21.6%), chills (17.6%), dizziness (9.8%), and bone pain (7.8%). No cardiac or hematologic adverse events occurred. Conclusion: Adjuvant therapy with trastuzumab for 6 months resulted in a clinical benefit in patients with HER2-positive breast cancer.

AB - Objective: The optimal duration of adjuvant trastuzumab treatment in patients with HER2-positive breast cancer is not known. The aim of this study was to evaluate the efficacy of 6 months of adjuvant trastuzumab treatment in patients with stage II or III HER2-positive breast cancer. Methods: The records of patients with HER2-positive stage II or III breast cancer who were admitted to the Breast Center of Taipei Medical University Hospital and Yuan's General Hospital between 2000 and 2008 were reviewed. All patients received adjuvant trastuzumab at an initial dose of 4 mg/kg followed by a maintenance dose of 2 mg/kg/week for 22 weeks in combination with chemotherapy. Results: A total of 51 patients were included with a mean age of 46.9 years. Approximately 55% of the patients had stage III disease. The mean follow-up time from initiation of treatment was 45.2 months (range, 0.9 to 85 months). During follow-up, 46 patients (90.2%) did not experience tumor recurrence. The mean estimated disease free survival was 80.2 months. The estimated 1- , 2-, 5-, and 7-yearsurvival rates were 97.9%, 93.1%, 93.1%, and 93.1%, respectively. The most common adverse effects were gastrointestinal symptoms (21.6%), chills (17.6%), dizziness (9.8%), and bone pain (7.8%). No cardiac or hematologic adverse events occurred. Conclusion: Adjuvant therapy with trastuzumab for 6 months resulted in a clinical benefit in patients with HER2-positive breast cancer.

KW - 2 positive

KW - Breast cancer

KW - Clinical benefit

KW - Her

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84880428236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880428236&partnerID=8YFLogxK

U2 - 10.7314/APJCP.2013.14.3.1981

DO - 10.7314/APJCP.2013.14.3.1981

M3 - Article

C2 - 23679303

AN - SCOPUS:84880428236

VL - 14

SP - 1981

EP - 1984

JO - Asian Pacific Journal of Cancer Prevention

JF - Asian Pacific Journal of Cancer Prevention

SN - 1513-7368

IS - 3

ER -